The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 22, 2009
Filed:
Feb. 17, 2006
Samuel Fournier Lockwood, Lago Vista, TX (US);
Sean O'malley, Honolulu, HI (US);
David G. Watumull, Honolulu, HI (US);
Laura M. Hix, Honolulu, HI (US);
Henry Jackson, Honolulu, HI (US);
Geoff Nadolski, Kaaawa, HI (US);
Samuel Fournier Lockwood, Lago Vista, TX (US);
Sean O'Malley, Honolulu, HI (US);
David G. Watumull, Honolulu, HI (US);
Laura M. Hix, Honolulu, HI (US);
Henry Jackson, Honolulu, HI (US);
Geoff Nadolski, Kaaawa, HI (US);
Cardax Pharmaceuticals, Inc., Aiea, HI (US);
Abstract
A method for inhibiting and/or ameliorating the occurrence of diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals in a subject whereby a subject is administered a carotenoid structural analog, either alone or in combination with another carotenoid analog, or co-antioxidant formulation. The analog or analog combination is administered such that the subject's risk of experiencing diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals may be thereby reduced. The analog or analog combination may be administered to a subject for the inhibition and/or amelioration of ischemia-reperfusion injury. The analog or analog combination may be administered to a subject for the inhibition and/or amelioration of liver disease. The analog or analog combination may be administered to a subject for the inhibition and/or amelioration of cancer. The analog or analog combination may be administered to a subject for the inhibition and/or amelioration of cardiac arrhythmia and/or sudden cardiac death. The analog or analog combination may be administered to a subject for the inhibition and/or amelioration of any disease that involves production of reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals. In one embodiment, a water-soluble and/or water-dispersible astaxanthin analog is particularly effective. This invention further includes pharmaceutical compositions comprising structural carotenoid analogs either alone or in combination.